Pneumococcal serotypes in adults hospitalized with community-acquired pneumonia in Greece using urinary antigen detection tests: the EGNATIA study, November 2017 – April 2019

Pneumococcal serotypes in adults hospitalized with community-acquired pneumonia in Greece using urinary antigen detection tests: the EGNATIA study, November 2017 – April 2019

Greece introduced a 13-valent pneumococcal conjugate vaccine (PCV13) into the infant national immunization program in 2010 (3 + 1 schedule until June 2019). Since 2015, PCV13 has been recommended for adults aged 19–64 years with comorbidities and adults ≥65 years sequentially with 23-valent pneumoco...

Full description

Bibliographic Details
Main Authors: Adamantia Liapikou, Athanasios Konstantinidis, Vasiliki Kossyvaki, John Skiadas, Damianos Menegas, Cristina Méndez, Rohini Beavon, Elizabeth Begier, Bradford D. Gessner, Haralampos Milionis, Vasilios Tsimihodimos, Gerasimos Baxevanos, Theodora Argiriadou, Chrysavgi Terrovitou, Michael Toumbis, The EGNATIA Study Group
Format: Article
Language:English
Published: Taylor & Francis Group 2022-11-01
Series:Human Vaccines & Immunotherapeutics
Subjects:
hospitalized community-acquired pneumonia
pneumococcus
13-valent pneumococcal conjugate vaccine
urinary antigen detection test
adult
greece
Online Access:http://dx.doi.org/10.1080/21645515.2022.2079923

Internet

http://dx.doi.org/10.1080/21645515.2022.2079923

Similar Items